IGF-I abuse in sport: Current knowledge and future prospects for detection

Growth Hormone and IGF Research

Volumn 19, Issue 4, 2009, Pages 408-411

  Guha, Nishan ^a   Sönksen, Peter H ^a   Holt, Richard I G ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Abuse; Doping; GH; IGF I; Sport

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; HUMAN GROWTH HORMONE; INSULIN; MECASERMIN RINFABATE; OSTEOCALCIN; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ARTICLE; ATHLETIC PERFORMANCE; BLOOD SAMPLING; BODY COMPOSITION; BONE TURNOVER; CARBOHYDRATE METABOLISM; DIABETES MELLITUS; DOPING; DRUG INDUCED HEADACHE; FITNESS; FLUID RETENTION; GROWTH DISORDER; GROWTH HORMONE DEFICIENCY; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HYPOGLYCEMIA; INJECTION SITE ERYTHEMA; INSULIN RESISTANCE; LIPID METABOLISM; LIPID OXIDATION; LIPOHYPERTROPHY; LIPOLYSIS; LIVER FUNCTION TEST; MYALGIA; PAIN; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SYNTHESIS; SIDE EFFECT;

ATHLETES; BODY COMPOSITION; CARBOHYDRATES; DOPING IN SPORTS; GLYCOGEN; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; RECOMBINANT PROTEINS; SPORTS; SUBSTANCE ABUSE DETECTION;

EID: 67749135257     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2009.04.017     Document Type: Article

References (48)

1. Le Roith D., Bondy C., Yakar S., Liu J.L., and Butler A. The somatomedin hypothesis: 2001. Endocr. Rev. 22 (2001) 53-74
2. WADA. The 2008 Prohibited List: International Standard, 2008 Available from: (cited 30 March 2008).
3. TM. Expert. Opin. Drug Metab. Toxicol. 4 (2008) 311-324
4. S. Veggeberg. Beyond steroids, 1996. Available from: (cited 2008 16 May 2008).
5. Eliakim A., Brasel J.A., Mohan S., Barstow T.J., Berman N., and Cooper D.M. Physical fitness. Endurance training, and the growth hormone-insulin-like growth factor I system in adolescent females. J. Clin. Endocrinol. Metab. 81 (1996) 3986-3992
6. Fryburg D.A., Gelfand R.A., and Barrett E.J. Growth hormone acutely stimulates forearm muscle protein synthesis in normal humans. Am. J. Physiol. 260 (1991) E499-504
7. Hansen T.K. Pharmacokinetics and acute lipolytic actions of growth hormone. Impact of age, body composition, binding proteins, and other hormones. Growth Horm. IGF Res. 12 (2002) 342-358
8. Graham M.R., Baker J.S., Evans P., et al. Short-term recombinant human growth hormone administration improves respiratory function in abstinent anabolic-androgenic steroid users. Growth Horm. IGF Res. 17 (2007) 328-335
9. Laron Z., Blum W., Chatelain P., et al. Classification of growth hormone insensitivity syndrome. J. Pediatr. 122 (1993) 241
10. Chernausek S.D., Backeljauw P.F., Frane J., Kuntze J., and Underwood L.E. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J. Clin. Endocrinol. Metab. 92 (2007) 902-910
11. Mauras N., Martinez V., Rini A., and Guevara-Aguirre J. Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism. J. Clin. Endocrinol. Metab. 85 (2000) 3036-3042
12. K. Back, H.J. Arnqvist, Changes in insulin and IGF-I receptor expression during differentiation of human preadipocytes, Growth Horm. IGF Res. (2008).
13. Turkalj I., Keller U., Ninnis R., Vosmeer S., and Stauffacher W. Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid, and leucine metabolism in man. J. Clin. Endocrinol. Metab. 75 (1992) 1186-1191
14. Fryburg D.A. Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism. Am. J. Physiol. 267 (1994) E331-E336
15. Russell-Jones D.L., Umpleby A.M., Hennessy T.R., et al. Use of a leucine clamp to demonstrate that IGF-I actively stimulates protein synthesis in normal humans. Am. J. Physiol. 267 (1994) E591-E598
16. Pupim L.B., Flakoll P.J., Yu C., and Ikizler T.A. Recombinant human growth hormone improves muscle amino acid uptake and whole-body protein metabolism in chronic hemodialysis patients. Am. J. Clin. Nutr. 82 (2005) 1235-1243
17. Guler H.P., Zapf J., and Froesch E.R. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N. Engl. J. Med. 317 (1987) 137-140
18. Boulware S.D., Tamborlane W.V., Rennert N.J., Gesundheit N., and Sherwin R.S. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults. J. Clin. Invest. 93 (1994) 1131-1139
19. Russell-Jones D.L., Bates A.T., Umpleby A.M., et al. A comparison of the effects of IGF-I and insulin on glucose metabolism, fat metabolism and the cardiovascular system in normal human volunteers. Eur. J. Clin. Invest. 25 (1995) 403-411
20. Saukkonen T., Shojaee-Moradie F., Williams R.M., et al. Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes. Diabetes 55 (2006) 2365-2370
21. Simpson H.L., Jackson N.C., Shojaee-Moradie F., et al. Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes. J. Clin. Endocrinol. Metab. 89 (2004) 425-432
22. Caro J.F., Poulos J., Ittoop O., Pories W.J., Flickinger E.G., and Sinha M.K. Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J. Clin. Invest. 81 (1988) 976-981
23. McDonald A., Williams R.M., Regan F.M., Semple R.K., and Dunger D.B. IGF-I treatment of insulin resistance. Eur. J. Endocrinol. 157 Suppl. 1 (2007) S51-S56
24. Frick F., Oscarsson J., Vikman-Adolfsson K., Ottosson M., Yoshida N., and Eden S. Different effects of IGF-I on insulin-stimulated glucose uptake in adipose tissue and skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 278 (2000) E729-E737
25. Essen B. Intramuscular substrate utilization during prolonged exercise. Ann. N.Y. Acad. Sci. 301 (1977) 30-44
26. Furling D., Marette A., and Puymirat J. Insulin-like growth factor I circumvents defective insulin action in human myotonic dystrophy skeletal muscle cells. Endocrinology 140 (1999) 4244-4250
27. Cheetham T.D., Holly J.M., Clayton K., Cwyfan-Hughes S., and Dunger D.B. The effects of repeated daily recombinant human insulin-like growth factor I administration in adolescents with type 1 diabetes. Diabet. Med. 12 (1995) 885-892
28. Kemp S.F. Mecasermin rinfabate. Drugs Today (Barc) 43 (2007) 149-155
29. Kemp S.F., Fowlkes J.L., and Thrailkill K.M. Efficacy and safety of mecasermin rinfabate. Expert. Opin. Biol. Ther. 6 (2006) 533-538
30. Chantelau E. Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br. J. Ophthalmol. 82 (1998) 725-730
31. Simpson H.L., Umpleby A.M., and Russell-Jones D.L. Insulin-like growth factor-I and diabetes. A review. Growth Horm. IGF Res. 8 (1998) 83-95
32. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329 (1993) 977-986.
33. Kuzuya H., Matsuura N., Sakamoto M., et al. Trial of insulin-like growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 42 (1993) 696-705
34. Yokoya S., Suwa S., Maesaka H., and Tanaka T. Immunoreactive somatomedin C/insulin-like growth factor I in urine from normal subjects, pituitary dwarfs, and acromegalics. Pediatr. Res. 23 (1988) 151-154
35. Hall C.M., Gill M.S., Foster P., et al. Relationship between serum and urinary insulin-like growth factor-I through childhood and adolescence their use in the assessment of disordered growth. Clin. Endocrinol. (Oxf) 50 (1999) 611-618
36. De Palo E.F., Gatti R., Lancerin F., et al. Effects of acute, heavy-resistance exercise on urinary peptide hormone excretion in humans. Clin. Chem. Lab. Med. 41 (2003) 1308-1313
37. Kazlauskas R., Howe C., and Trout G. Strategies for rhEPO detection in sport. Clin. J. Sport Med. 12 (2002) 229-235
38. Saugy M., Cardis C., Robinson N., and Schweizer C. Test methods: anabolics. Baillieres Best Pract. Res. Clin. Endocrinol. Metab. 14 (2000) 111-133
39. Bowers L.D. Analytical advances in detection of performance-enhancing compounds. Clin. Chem. 43 (1997) 1299-1304
40. Bredehoft M., Schanzer W., and Thevis M. Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Commun. Mass Spectrom. 22 (2008) 477-485
41. Chung L., Clifford D., Buckley M., and Baxter R.C. Novel biomarkers of human growth hormone action from serum proteomic profiling using protein chip mass spectrometry. J. Clin. Endocrinol. Metab. 91 (2006) 671-677
42. Wallace J.D., Cuneo R.C., Baxter R., et al. Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal in trained adult males: a potential test for GH abuse in sport. J. Clin. Endocrinol. Metab. 84 (1999) 3591-3601
43. Wallace J.D., Cuneo R.C., Lundberg P.A., et al. Responses of markers of bone and collagen turnover to exercise, growth hormone (GH) administration, and GH withdrawal in trained adult males. J. Clin. Endocrinol. Metab. 85 (2000) 124-133
44. McHugh C.M., Park R.T., Sonksen P.H., and Holt R.I. Challenges in detecting the abuse of growth hormone in sport. Clin. Chem. 51 (2005) 1587-1593
45. Powrie J.K., Bassett E.E., Rosen T., et al. Detection of growth hormone abuse in sport. Growth Horm. IGF Res. 17 (2007) 220-226
46. Carroll P.V., Umpleby M., Alexander E.L., et al. Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment. Clin. Endocrinol. (Oxf) 49 (1998) 739-746
47. Clemmons D.R., Sleevi M., Allan G., and Sommer A. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes. J. Clin. Endocrinol. Metab. 92 (2007) 2652-2658
48. Longobardi S., Keay N., Ehrnborg C., et al. Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 Study Group. J. Clin. Endocrinol. Metab. 85 (2000) 1505-1512